Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population
ACTIVE_NOT_RECRUITING
Status
Conditions
- Chronic Myeloid Leukemia
- Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission
- Chronic Myeloid Leukemia in Remission
Interventions
- OTHER: Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Withdrawal
- DRUG: Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Re-initiation
Sponsor
Baylor College of Medicine